

Gastrointestinal Flowcharts

Revised: February 9, 2018

Gastric/GE Junction

*For Esophageal/GE Junction, see Esophageal/GE Junction page

Metastatic

2nd Line and Beyond

Advanced minimum of 1, maximum of 3 prior lines. Must have included Fluoropyrimide

EGFR Expressing

VICC GI 15126
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors
*Gastric- Cohort Ibrutinib plus Docetaxel
***Call for slots**
1-615-936-5847 or 1-800-811-8480

VICC GI 13114
A Multi Part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination with Paclitaxel or Pembrolizumab in Patients with Relapsed or Refractory Esophagogastric Malignancies
***Arm E**

Gastroesophageal HER 2+ (Cohort 1D)

VICC MD 1403
An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2) Mutations or EGFR Gene Amplification
*No EGFR previously

Mesothelin Expressing

Trial Pending

Genomic Based Studies
1403 – HER2 pos
15126 – EGFR expressing

KEY

 Accrual on hold

 Open

Check the Phase 1 flowchart for additional clinical trials

Check the Molecular Multi-disease flowchart

Check the Advanced Solid Tumors Multi-Disease flowchart